Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

Auteurs

R. Condorelli, F. Mosele, B. Verret, T. Bachelot, P.L. Bedard, J. Cortes, D.M. Hyman, D. Juric, I. Krop, I. Bieche, C. Saura, C. Sotiriou, F. Cardoso, S. Loibl, F. Andre, N.C. Turner